Cover Image
Market Research Report
Product code 
1058836

Global Automated Insulin Delivery Systems Market - 2021-2028

Published: | DataM Intelligence | 185 Pages | Delivery time: 2 business days

Price

Back to Top
Global Automated Insulin Delivery Systems Market - 2021-2028
Published: February 16, 2022
DataM Intelligence
Content info: 185 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

The global automated insulin delivery systems market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Automated insulin delivery systems are automated (or semi-automated) systems that enable patients with diabetes, mainly type 1, to control their blood glucose levels by automatically adjusting insulin delivery.

Market Dynamics

Advancement in next-generation automatic insulin delivery systems is expected to drive market growth.

RocketAP, a brand-new automated insulin delivery (AID) algorithm, helped adolescents with type 1 diabetes stay more time in range after meals, even when they didn't take mealtime (bolus) insulin, according to tiny but interesting research. RocketAP is similar to Control-IQ, but it has a unique system feature that can detect unscheduled meals and provide bolus insulin fast to minimize high blood sugar levels afterward (hyperglycemia). Moreover, a study was conducted where Tandem insulin pumps and Dexcom G6 CGMs were used, and the results were impressive and could indicate the first steps toward a fully closed-loop algorithm. Thus, from the above statements, the market is expected to boost in the forecast period.

The drawbacks associated with automated insulin delivery systems are expected to hamper market growth.

Infusion sets that are kinked or unintentionally torn out, malfunctioning pumps, dead batteries, and infusion site adhesion concerns are major insulin pump issues. There are also budget pressures when it comes to reimbursement. Pumps, CGM sensors, and AID systems are all expensive, and most people can only afford to use them if they have insurance. Even DIY systems need customers to pay a yearly charge for a software development license and the upfront price of any hardware needed to link their pump and algorithm. There is a risk of skin infection or allergic reaction by infusion pumps. Thus, the market is expected to get hampered in the forecast period from the above statements.

COVID-19 Impact Analysis

The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on the automated insulin delivery systems market. In hospitalized patients with COVID-19, type 1 and type 2 diabetes are associated with an increased risk of death, with a larger number of deaths in people with type 1 and type 2 diabetes living in the most deprived neighborhoods than those living in the least deprived districts. Moreover, hyperglycemia and obesity are linked to COVID-19 mortality in persons with diabetes. Secondly, SARS-CoV-2 can, directly and indirectly, impact glucose metabolism by triggering beta cell death and raising insulin resistance. Self-management of type 1 diabetes (T1D) can be difficult, requiring numerous daily insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), all of which are guided by glucose self-monitoring.

Additionally, the pandemic is interrupting the supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Reusable Insulin Pens segment is expected to hold the largest market share in automated insulin delivery systems market

The reusable insulin pens segment is expected to dominate in 2020. The most significant advantages are durability, which helps overcome the barrier of huge storage space necessary for disposable insulin pens, and the ability to carry a 3-5-day supply. Meanwhile, reusable insulin pens are more accurate in meeting dose accuracy according to international standards (ISO-11608-1). They are equipped with additional features such as audible, visual, and tactile feedback during dose dialing to aid application and reduce the risk of human errors during handling. In addition, the newer reusable insulin pens have the advantage of adjusting a selected dose without losing insulin, as opposed to previous pens with one-directional dial constraints that made it impossible to dial "back" the dose.

Additionally, the process of resetting the pen after changing to a new cartridge in older reusable pens was quite tough, as the piston rod had to be re-wound to its starting point. On the other hand, the newest reusable pens allow the user to insert the piston rod back into the pen rather than turning it. Reusable pens may be less expensive than vials and syringes, in addition to the benefits listed above. Furthermore, these insulin delivery pens are environmentally benign and may have an advantage over disposable pens in contributing to less plastic waste. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global automated insulin delivery systems market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of the diabetic population, technological advancement in the devices, well-established healthcare facilities in the region, acquisition and collaboration by the market players are some of the factors due to which the market is expected to boost in the forecast period. For instance, According to the Centers for Disease Control (CDC), diabetes was the seventh leading cause of death in the United States. In 2018, an estimated 1.5 million new cases of diabetes were diagnosed among U.S. adults aged 18 years or older. In contrast, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes, and nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents.

Moreover, Abbott and Tandem Diabetes Care signed an agreement in June 2020 to create and market Abbott's continuous glucose monitoring (CGM) systems alongside Tandem's revolutionary insulin delivery systems to provide diabetes care solutions that address the gap in the market. Insulet also teamed with the other two businesses in February 2020 to advance diabetes management technology. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the automated insulin delivery systems market are Medtronic, Novo Nordisk, Insulet Corporation , Tandem Diabetes Care, Inc, Ypsomed AG, F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Biocon, Bigfoot Biomedical, Inc. and sanofi-aventis U.S. LLC.

Medtronic Plc:

Overview:

Medtronic plc is an American-Irish registered medical device company primarily operating in the United States. It has an operational and executive headquarters in Fridley, Minnesota, in the US. Moreover, it develops and manufactures devices and therapies to treat more than 30 chronic diseases, including heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders and diabetes. It is operated in 140 countries and employs over 104,950 people.

Product Portfolio:

MiniMed 670G system: The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user-selectable rates) and administration of insulin boluses (in user-selectable amounts) to manage type 1 diabetes mellitus in persons seven years of age and older.

Why Purchase the Report?

Visualize the composition of the automated insulin delivery systems market segmentation by device type, insulin pumps, pen needles, end user and region highlighting the key commercial assets and players.

Identify commercial opportunities in automated insulin delivery systems market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of automated insulin delivery systems market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global automated insulin delivery systems market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturer

Market Segmentation

Global Automated Insulin Delivery Systems Market - By Device Type

Reusable Insulin Pens

Disposable Insulin Pens

Global Automated Insulin Delivery Systems Market - By Insulin Pumps

External/ Tethered Pumps

Implanted Insulin pump (IIP)

Patch Pumps

Closed loop insulin pump

Others

Global Automated Insulin Delivery Systems Market - By Pen Needles

Standard Pen Needles

Safety Pen Needles

Others

Global Automated Insulin Delivery Systems Market - By End user

Hospitals

Clinics

Homecare

Others

Global Automated Insulin Delivery Systems Market - By Region

North America

South America

Europe

Asia

Middle East & Africa

Product Code: DMMD4692

Table of Contents

1. Global Automated Insulin Delivery Systems Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Automated Insulin Delivery Systems Market - Market Definition and Overview

3. Global Automated Insulin Delivery Systems Market - Executive Summary

  • 3.1. Market Snippet by Device Type
  • 3.2. Market Snippet by Insulin Pumps
  • 3.3. Market Snippet by Pen Needles
  • 3.4. Market Snippet by End User
  • 3.5. Market Snippet by Region

4. Global Automated Insulin Delivery Systems Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in next-generation automatic insulin delivery systems is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The drawbacks associated with automated insulin delivery systems are expected to hamper market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Automated Insulin Delivery Systems Market - Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Unmet Needs

6. Global Automated Insulin Delivery Systems Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Automated Insulin Delivery Systems Market - By Device Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 7.1.2. Market Attractiveness Index, By Device Type Segment
  • 7.2. Reusable Insulin Pens*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Disposable Insulin Pens

8. Global Automated Insulin Delivery Systems Market - By Insulin Pumps

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pumps
    • 8.1.2. Market Attractiveness Index, By Insulin Pumps Segment
  • 8.2. External/ Tethered Pumps*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Implanted Insulin pump (IIP)
  • 8.4. Patch Pumps
  • 8.5. Closed loop insulin pump
  • 8.6. Others

9. Global Automated Insulin Delivery Systems Market - By Pen Needles

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 9.1.2. Market Attractiveness Index, By Pen Needles Segment
  • 9.2. Standard Pen Needles*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Safety Pen Needles
  • 9.4. Others

10. Global Automated Insulin Delivery Systems Market - By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Homecare
  • 10.5. Others

11. Global Automated Insulin Delivery Systems Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pump
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pump
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pump
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pump
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Device Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Insulin Pump
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Pen Needles
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Global Automated Insulin Delivery Systems Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Global Automated Insulin Delivery Systems Market- Company Profiles

  • 13.1. Medtronic*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Novo Nordisk
  • 13.3. Insulet Corporation
  • 13.4. Tandem Diabetes Care, Inc.
  • 13.5. Ypsomed AG
  • 13.6. F. Hoffmann-La Roche Ltd.
  • 13.7. Becton, Dickinson and Company
  • 13.8. Biocon
  • 13.9. Bigfoot Biomedical, Inc.
  • 13.10. sanofi-aventis U.S. LLC

LIST NOT EXHAUSTIVE

14. Global Automated Insulin Delivery Systems Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us